메뉴 건너뛰기




Volumn 48, Issue 9, 2017, Pages 734-740

Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INSULIN; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

EID: 85029705423     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20170829-08     Document Type: Article
Times cited : (26)

References (34)
  • 1
    • 84859030420 scopus 로고    scopus 로고
    • Global prevalence and major risk factors of diabetic retinopathy
    • Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
    • (2012) Diabetes Care , vol.35 , Issue.3 , pp. 556-564
    • Yau, J.W.1    Rogers, S.L.2    Kawasaki, R.3
  • 2
    • 78049293726 scopus 로고    scopus 로고
    • Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
    • Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
    • (2010) Ophthalmology , vol.117 , Issue.11 , pp. 2146-2151
    • Nguyen, Q.D.1    Shah, S.M.2    Khwaja, A.A.3
  • 3
    • 84856397889 scopus 로고    scopus 로고
    • Diabetic retinopathy and inflammation: Novel therapeutic targets
    • Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19(1):52-59.
    • (2012) Middle East Afr J Ophthalmol , vol.19 , Issue.1 , pp. 52-59
    • Rangasamy, S.1    McGuire, P.G.2    Das, A.3
  • 4
    • 0033551811 scopus 로고    scopus 로고
    • Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors
    • Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-23467.
    • (1999) J Biol Chem , vol.274 , Issue.33 , pp. 23463-23467
    • Antonetti, D.A.1    Barber, A.J.2    Hollinger, L.A.3    Wolpert, E.B.4    Gardner, T.W.5
  • 5
    • 84934932422 scopus 로고    scopus 로고
    • Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy
    • Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137-148.
    • (2015) Pharmacol Res , vol.99 , pp. 137-148
    • Behl, T.1    Kotwani, A.2
  • 6
    • 84908118639 scopus 로고    scopus 로고
    • Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
    • Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
    • (2014) Ophthalmology , vol.121 , Issue.10 , pp. 1904-1914
    • Boyer, D.S.1    Yoon, Y.H.2    Belfort, R.3
  • 7
    • 84925423332 scopus 로고    scopus 로고
    • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
    • Diabetic Retinopathy Clinical Research N
    • Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
    • (2015) N Engl J Med , vol.372 , Issue.13 , pp. 1193-1203
    • Wells, J.A.1    Glassman, A.R.2
  • 8
    • 79953311138 scopus 로고    scopus 로고
    • The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
    • Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
    • (2011) Ophthalmology , vol.118 , Issue.4 , pp. 615-625
    • Mitchell, P.1    Bandello, F.2    Schmidt-Erfurth, U.3
  • 9
    • 84863401792 scopus 로고    scopus 로고
    • Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE
    • Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
    • (2012) Ophthalmology , vol.119 , Issue.4 , pp. 789-801
    • Nguyen, Q.D.1    Brown, D.M.2    Marcus, D.M.3
  • 10
    • 84899837995 scopus 로고    scopus 로고
    • Current status in diabetic macular edema treatments
    • Romero-Aroca P. Current status in diabetic macular edema treatments. World J Diabetes. 2013;4(5):165-169.
    • (2013) World J Diabetes , vol.4 , Issue.5 , pp. 165-169
    • Romero-Aroca, P.1
  • 11
    • 84908897529 scopus 로고    scopus 로고
    • Intravitreal aflibercept for diabetic macular edema
    • Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
    • (2014) Ophthalmology , vol.121 , Issue.11 , pp. 2247-2254
    • Korobelnik, J.F.1    Do, D.V.2    Schmidt-Erfurth, U.3
  • 12
    • 79251606719 scopus 로고    scopus 로고
    • Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study
    • Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
    • (2010) Diabetes Care , vol.33 , Issue.11 , pp. 2399-2405
    • Massin, P.1    Bandello, F.2    Garweg, J.G.3
  • 13
    • 12744266491 scopus 로고    scopus 로고
    • Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown
    • Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80(2):249-258.
    • (2005) Exp Eye Res , vol.80 , Issue.2 , pp. 249-258
    • Edelman, J.L.1    Lutz, D.2    Castro, M.R.3
  • 14
    • 50249149459 scopus 로고    scopus 로고
    • A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network 1449.e1-10
    • Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-1449, 1449.e1-10.
    • (2008) Ophthalmology , vol.115 , Issue.9 , pp. 1447-1449
  • 15
    • 42549132257 scopus 로고    scopus 로고
    • Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors
    • Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors. Retina. 2008;28(4):573-580.
    • (2008) Retina , vol.28 , Issue.4 , pp. 573-580
    • Vasconcelos-Santos, D.V.1    Nehemy, P.G.2    Schachat, A.P.3    Nehemy, M.B.4
  • 16
    • 84860197211 scopus 로고    scopus 로고
    • Diabetic macular edema
    • Lang GE. Diabetic macular edema. Ophthalmologica. 2012;227 Suppl 1:21-29.
    • (2012) Ophthalmologica , vol.227 , pp. 21-29
    • Lang, G.E.1
  • 17
    • 0012431804 scopus 로고    scopus 로고
    • Report of the expert committee on the diagnosis and classification of diabetes mellitus
    • Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
    • Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20.
    • (2003) Diabetes Care , vol.26 , pp. S5-20
  • 18
    • 0022347471 scopus 로고
    • Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group
    • No authors listed. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.
    • (1985) Arch Ophthalmol , vol.103 , Issue.12 , pp. 1796-1806
  • 19
    • 84856404530 scopus 로고    scopus 로고
    • Role of inflammation in the pathogenesis of diabetic retinopathy
    • El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19(1):70-74.
    • (2012) Middle East Afr J Ophthalmol , vol.19 , Issue.1 , pp. 70-74
    • El-Asrar, A.M.1
  • 20
    • 84868208071 scopus 로고    scopus 로고
    • Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results
    • Diabetic Retinopathy Clinical Research N
    • Diabetic Retinopathy Clinical Research N, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results. Ophthalmology. 2012;119(11):2312-2318.
    • (2012) Ophthalmology , vol.119 , Issue.11 , pp. 2312-2318
    • Elman, M.J.1    Qin, H.2
  • 21
    • 58149242792 scopus 로고    scopus 로고
    • Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema
    • Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053-1060.
    • (2008) Retina , vol.28 , Issue.8 , pp. 1053-1060
    • Kook, D.1    Wolf, A.2    Kreutzer, T.3
  • 22
    • 67650043196 scopus 로고    scopus 로고
    • Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial
    • Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina. 2009;29(3):292-299.
    • (2009) Retina , vol.29 , Issue.3 , pp. 292-299
    • Lam, D.S.1    Lai, T.Y.2    Lee, V.Y.3
  • 23
    • 77952253587 scopus 로고    scopus 로고
    • Correlation between visual acuity and foveal microstructural changes in diabetic macular edema
    • Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010;30(5):774-780.
    • (2010) Retina , vol.30 , Issue.5 , pp. 774-780
    • Otani, T.1    Yamaguchi, Y.2    Kishi, S.3
  • 24
    • 78649824641 scopus 로고    scopus 로고
    • Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema
    • Alasil T, Keane PA, Updike JF, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology. 2010;117(12):2379-2386.
    • (2010) Ophthalmology , vol.117 , Issue.12 , pp. 2379-2386
    • Alasil, T.1    Keane, P.A.2    Updike, J.F.3
  • 25
    • 21244445737 scopus 로고    scopus 로고
    • Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema
    • Bakri SJ, Shah A, Falk NS, Beer PM. Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye (Lond). 2005;19:686-688.
    • (2005) Eye (Lond) , vol.19 , pp. 686-688
    • Bakri, S.J.1    Shah, A.2    Falk, N.S.3    Beer, P.M.4
  • 26
    • 84863232320 scopus 로고    scopus 로고
    • An increase in intraocular pressure after intravitreal steroid injection facilitates reduction of macular edema
    • Chae JB, Joe SG, Yang SJ, Lee JY, Kim JG, Yoon YH. An increase in intraocular pressure after intravitreal steroid injection facilitates reduction of macular edema. Eye (Lond). 2012;26(3):479-480.
    • (2012) Eye (Lond) , vol.26 , Issue.3 , pp. 479-480
    • Chae, J.B.1    Joe, S.G.2    Yang, S.J.3    Lee, J.Y.4    Kim, J.G.5    Yoon, Y.H.6
  • 27
    • 79961231326 scopus 로고    scopus 로고
    • Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
    • Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol. 2011;5:1011-1016.
    • (2011) Clin Ophthalmol , vol.5 , pp. 1011-1016
    • Marey, H.M.1    Ellakwa, A.F.2
  • 28
    • 84941313014 scopus 로고    scopus 로고
    • Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15
    • Aref AA, Scott IU, Oden NL, et al. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15. JAMA Ophthalmol. 2015;133(9):1022-1029.
    • (2015) JAMA Ophthalmol , vol.133 , Issue.9 , pp. 1022-1029
    • Aref, A.A.1    Scott, I.U.2    Oden, N.L.3
  • 29
    • 40949161371 scopus 로고    scopus 로고
    • A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection
    • Im L, Allingham RR, Singh I, Stinnett S, Fekrat S. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J Glaucoma. 2008;17(2):128-132.
    • (2008) J Glaucoma , vol.17 , Issue.2 , pp. 128-132
    • Im, L.1    Allingham, R.R.2    Singh, I.3    Stinnett, S.4    Fekrat, S.5
  • 31
    • 11144253482 scopus 로고    scopus 로고
    • Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection
    • Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138(6):1046-1048.
    • (2004) Am J Ophthalmol , vol.138 , Issue.6 , pp. 1046-1048
    • Inoue, M.1    Takeda, K.2    Morita, K.3    Yamada, M.4    Tanigawara, Y.5    Oguchi, Y.6
  • 32
    • 48149111861 scopus 로고    scopus 로고
    • Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye
    • Kamppeter BA, Cej A, Jonas JB. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology. 2008;115(8):1372-1375.
    • (2008) Ophthalmology , vol.115 , Issue.8 , pp. 1372-1375
    • Kamppeter, B.A.1    Cej, A.2    Jonas, J.B.3
  • 33
    • 77952889192 scopus 로고    scopus 로고
    • A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2
    • Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078-1086.e2.
    • (2010) Ophthalmology , vol.117 , Issue.6 , pp. 1078-1078e2
    • Michaelides, M.1    Kaines, A.2    Hamilton, R.D.3
  • 34
    • 84975698767 scopus 로고    scopus 로고
    • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial
    • Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359.
    • (2016) Ophthalmology , vol.123 , Issue.6 , pp. 1351-1359
    • Wells, J.A.1    Glassman, A.R.2    Ayala, A.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.